Close

Leerink Says Seattle Genetics' (SGEN) Pipeline Value Drivers Still Underappreciated

Go back to Leerink Says Seattle Genetics' (SGEN) Pipeline Value Drivers Still Underappreciated

Seattle Genetics and Agensys, an Affiliate of Astellas, Highlight Promising Enfortumab Vedotin (ASG-22ME) and ASG-15ME Phase 1 Data in Metastatic Urothelial Cancer at 2016 ESMO Congress

October 7, 2016 9:00 AM EDT

-Objective Response Rates Presented for Both Antibody-Drug Conjugate Programs-

-Enfortumab Vedotin Demonstrates 59 Percent Objective Response Rate at Recommended Phase 2 Dose of 1.25 mg/kg, Supporting Advancement of the Development Program-

BOTHELL, Wash. & NORTHBROOK, Ill.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (NASDAQ: SGEN) and Agensys, an affiliate of Astellas, today presented updated clinical data... More

Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2016 Financial Results on October 27, 2016

October 6, 2016 8:00 AM EDT

BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its third quarter 2016 financial results on Thursday, October 27 after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:

LIVE access on Thursday, October 27, 20161:30 p.m. Pacific Time / 4:30 p.m. Eastern Time

Telephone 888-208-1814 (domestic) or 719-325-2444... More